An observational study of patients receiving T-DXd for treatment of HER2+, and HER2-low unresectable and/or metastatic breast cancer

Study identifier:D9673R00025

ClinicalTrials.gov identifier:NCT05592483

EudraCT identifier:N/A

CTIS identifier:N/A

Will Be Recruiting

Official Title

A multi-center, multi-country prospective observational study of patients initiating T-DXd in the first or second treatment line for HER2+, and HER2-low unresectable and/or metastatic breast cancer

Medical condition

Breast Cancer

Phase

N/A

Healthy volunteers

No

Study drug

-

Sex

All

Actual enrollment

750

Study type

Observational

Age

18 Years - 130 Years

Date

Study Start Date: 31 May 2023
Estimated Primary Completion Date: 31 Dec 2025
Estimated Study Completion Date: 31 Dec 2025

Study design

Allocation: N/A
Endpoint Classification: -
Intervention Model: -
Masking: -
Primary Purpose: -

Verification:

Verified 01 May 2023 by AstraZeneca

Sponsors

AstraZeneca

Collaborators

-

Inclusion and exclusion criteria